Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Hormone receptor (HR) + breast cancer (BC) causes most BC-related deaths, calling for improved therapeutic approaches. Despite expectations, immune checkpoint blockers (ICBs) are poorly active in patients with HR + BC, in part reflecting the lack of preclinical models that recapitulate disease progression in immunocompetent hosts. We demonstrate that mammary tumors driven by medroxyprogesterone acetate (M) and 7,12-dimethylbenz[a]anthracene (D) recapitulate several key features of human luminal B HR + HER2 − BC, including limited immune infiltration and poor sensitivity to ICBs. M/D-driven oncogenesis is accelerated by immune defects, demonstrating that M/D-driven tumors are under immunosurveillance. Safe nutritional measures including nicotinamide (NAM) supplementation efficiently delay M/D-driven oncogenesis by reactivating immunosurveillance. NAM also mediates immunotherapeutic effects against established M/D-driven and transplantable BC, largely reflecting increased type I interferon secretion by malignant cells and direct stimulation of immune effector cells. Our findings identify NAM as a potential strategy for the prevention and treatment of HR + BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The microbiota synthesizes vitamins from the B series [76][77][78][79] that favor tissue homeostasis and immunosurveillance.”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Self-citationSystematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Fast, sensitive and accurate integration of single-cell data with Harmony
Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R., & Raychaudhuri, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0619-0 · Cited by 10,488
Aran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Amongst other changes, T cells infiltrating NAM-treated tumors exhibited (1) increased expression of genes involved in antigen recognition, including Cd3d, Cd3e, Cd3g, Cd8a and Cd8b1; (2) upregulation of effector molecules including granzyme B (GZMB) and Fas ligand (FASLG); (3) increased levels of surface activation m…”
BackgroundFinak, G., McDavid, A., Yajima, M., Deng, J., Gersuk, V., Shalek, A. K., Slichter, C. K., Miller, H. W., McElrath, M. J., Prlic, M., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0844-5 · Cited by 3,159
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Self-citation
Research works printed but not linked: 1
- Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. Preprint at https://www.biorxiv.org/content/10.1101/060012v2 (2019). · doi:10.1101/060012v2
Cited by
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Self-citationMitochondrial control of inflammation
Marchi, S., Guilbaud, E., Tait, S. W. G., Yamazaki, T., & Galluzzi, L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00760-x · Cited by 1,027
Self-citationIntratumoral heterogeneity in cancer progression and response to immunotherapy
Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01233-9 · Cited by 826
Self-citationMittelbrunn, M., & Kroemer, G. (2021) · Nature Immunology · doi:10.1038/s41590-021-00927-z · Cited by 702
Self-citationThe hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Self-citation
Metadata
- Authors
- Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., Aranda, F., Durand, S., Boissonnas, A., Fucikova, J., Senovilla, L., Enot, D., Hensler, M., Kremer, M., Stoll, G., Hu, Y., Massa, C., Formenti, S. C., Seliger, B., Elemento, O., Spisek, R., André, F., Zitvogel, L., Delaloge, S., Kroemer, G., & Galluzzi, L.
- Affiliations
- Inserm (FR)
- Université Paris-Sud (FR)
- Weill Cornell Medicine (US)
- Centre National de la Recherche Scientifique (FR)
- Charles University (CZ)
- Sotio (Czechia) (CZ)
- Martin Luther University Halle-Wittenberg (DE)
- Institut Gustave Roussy (FR)
- Karolinska University Hospital (SE)
- Université Paris Cité (FR)
- Corresponding author
- Kroemer, Guido
- Galluzzi, Lorenzo
- ORCID
- Buqué, Aitziber
- Bloy, Norma
- Iribarren, Kristina
- Humeau, Juliette
- Pol, Jonathan G.
- Yamazaki, Takahiro
- Sato, Ai
- Aranda, Fernando
- Durand, Sylvère
- Boissonnas, Alexandre
- Fucikova, Jitka
- Senovilla, Laura
- Hensler, Michal
- Stoll, Gautier
- Hu, Yang
- Massa, Chiara
- Formenti, Silvia C.
- Seliger, Barbara
- Elemento, Olivier
- André, Fabrice
- Zitvogel, Laurence
- Delaloge, Suzette
- Kroemer, Guido
- Galluzzi, Lorenzo
- Venue
- Nature Communications
- Published
- 2020-07-30
- Volume
- 11
- Issue
- 1
- Pages
- 3819-3819
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7393498
- OpenAlex
- W3045997924
- Cited by
- 138
- References
- 71
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 19 · 2023: 24 · 2022: 25 · 2021: 28 · 2020: 7
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-09-17)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Defense (BC180476P1)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- hormone receptor-positive breast cancer, luminal B, immune surveillance, medroxyprogesterone acetate, 7,12-dimethylbenz(a)anthracene, mammary tumor model, nicotinamide, type I interferon, immunotherapy, cancer prevention, immune cell infiltration, immunocompetent model
- MeSH terms
- Animals, Breast Neoplasms, Female, Humans, Immunotherapy, Interferon Type I, Mammary Neoplasms, Experimental, Mice, Inbred BALB C, Mice, Inbred C57BL, Niacinamide, 9,10-Dimethyl-1,2-benzanthracene, Survival Analysis, Medroxyprogesterone Acetate, Mice, Knockout, Disease Progression, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. https://app.cochat.ai/papers/10.1038/s41467-020-17644-0
- The paper
- Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., Aranda, F., Durand, S., Boissonnas, A., Fucikova, J., Senovilla, L., Enot, D., Hensler, M., Kremer, M., Stoll, G., . . . Galluzzi, L. (2020). Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications. https://doi.org/10.1038/s41467-020-17644-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.